Anis Fahandej-Sadi’s Post

TLDR Biotech for June 26 - 27 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Novo Nordisk buys 2seventy bio’s Hemophilia A asset for $40M 🤝 + 1 more story 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Silence Therapeutics reports encouraging early Ph1 blood disorder data 🩸 + 2 more stories 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: WayPoint Bio launches to "test hundreds [of cell therapies] at once" 🤯 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Holoclara’s worm-derived therapies raise a $16M Series A 🪱 + 5 more stories 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: Vigil Therapeutics receive $40M strategic investment from Sanofi 💼 𝐌𝐞𝐫𝐠𝐞𝐫𝐬 & 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬: AbbVie brings the heat, buys Celsius Therapeutics for $250M cash 🔥 + 3 more stories 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Kite Pharma signs on to assess Cellares’ cell therapy manufacturing platform 🤖 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐬 & 𝐏𝐨𝐥𝐢𝐜𝐲: Medicare inches closer to covering weight loss drugs 💊 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: Eisai, Biogen's Leqembi launches in China 🚀 All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gT9Z6KEQ Or subscribe to get it straight to your inbox: https://lnkd.in/gecXctqM #tldrbiotech #biotechnews #pharmanews

Check out the latest Big Pharma Sharma post - summarized below in a linkedin post I published earlier today New subscribers get 1-week free. Catch up on all the content you may have missed by exploring our archives: https://lnkd.in/g37VRw3h

One of the major challenges in the field of biotherapeutics is the inefficient development pipeline, which hampers timely advancement and deployment. Another critical issue is poor therapeutic performance, which can limit the efficacy and applicability of these treatments. To address these problems, we have devised two unique solutions that aim to revolutionize the current landscape. One of them is Seqitope™ – a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. Visit our website to learn more about Seqitope™: https://lnkd.in/gg5EjZnR #Biotech #AntibodyTherapeutics #NextGenTherapeutics

As Biomica Ltd. shares positive preliminary results from their ongoing P1 trial of BMC128 in combination with nivolumab – Investigating the Asian Microbiome Biopharma market reveals #Solidtumors are the disease indication of most interest – Though with the expanding market of #ImmuneDiseases like #IBD & #Inflammation – How will we see the number of companies targeting this disease group rise? In a fast moving field, I’m looking forward to Beacon & Ada Lam joining the #MicrobiomeMovement Drug Development Summit to highlight industry’s global trends, including May’s movements from Beacon: 🦠20 New Trials: Rise Therapeutics (solid tumors), Miyarisan Pharmaceutical Company Ltd (kidney cancer), Xeno Biosciences (obesity) 🦠40 Trial Updates: Vedanta Biosciences, Inc., Pfizer, Janssen Inc., Biomica Ltd. , Evelo Biosciences, BiomX Inc 🦠8 New Companies: #Investment (Bison Capital, Galaxy Capital, North-East Family Office, Wenzhou Capital) & #Biopharma (Urobiome Therapeutics & CreatiPhage Biotechnology) 🦠Development in the Asian Market: 36% #LBP drugs involve an Asian collaborator See you in 4 weeks! More here: https://ter.li/tm8a5q

💊 𝐍𝐞𝐰 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐟𝐨𝐫 𝐚 𝐧𝐞𝐰 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐝𝐫𝐮𝐠 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 Advanced therapeutic modalities are changing the lives of patients but, behind that, they also shift the nature of competition in the pharmaceutical industry, introducing challenges in manufacturing and commercialisation. The sales of advanced therapeutic modalities are projected to reach $45 to $60 billion by 2027, underlining the expansion of the field. This excellent article from HBR highlights the need for new business strategies for these innovative drugs. Major points: ⚆ Manufacturing speed, cost, and consistency in the delivery of ATMs must become a priority. Biopharma companies must proactively manage their manufacturing strategy to ensure reliable, cost-competitive, and rapid ATM production at scale. ⚆ Supply chain management should consider whether to outsource production or invest in proprietary platforms to maintain control over critical intellectual property and supply chain, balancing the benefits of control against the costs and operational overhead. ⚆ Contract development and marketing organisations (CDMOs) must continue to invest in enabling tools, technologies, and talent to support innovation in the ATM ecosystem. Full article: https://lnkd.in/dz8mYgFQ #manufacturing #pharma #biotech #GMP #womeninbusiness #drjojo

📢  Pfizer has announced the discontinuation of OXBRYTA for Sickle Cell Disease (SCD) in all approved markets after data indicated a higher risk of vaso-occlusive crises and fatal events, which they consider outweigh the benefits of the treatment. ❗️This comes as a major blow for the company after having acquired the originator, Global Blood Therapeutics, for $5.4B in 2022. Regardless, Pfizer will push ahead with its other SCD candidates. ➡️ This decision may also serve as a potential catalyst for CRISPR Therapeutics and Vertex Pharmaceuticals' CASGEVY, the first approved Cas9 gene-edited therapy for SCD. 🌟 The future of SCD treatment is evolving rapidly, and gene-editing therapies could represent a significant advancement in early detection and management. #SickleCellDisease #GeneTherapy #CRISPR #Pfizer #Biotech

Discover the latest insights on the G-protein coupled receptors (GPCR) market from The Business Research Company. Projections indicate significant growth, reaching $3.18 billion by 2024 with a 7.1% CAGR, and $4.09 billion by 2028 at a 6.5% CAGR. Factors like drug discovery advancements and cancer prevalence are driving this expansion. Major players include Pfizer Inc. and Roche Holding AG. Investments by LifeArc Ventures and Eurofins Scientific's acquisition of Beacon Discovery underscore the industry's focus on GPCR-related research and drug discovery. For more Information: https://lnkd.in/g8CXGcT3 #gpcr #marketinsights #healthcareresearch #businessanalysis #tbrc📊🔬

📢 Lonza teams up to produce breakthrough Alzheimer's antibody 📰 Lonza has partnered with Acumen Pharmaceuticals, Inc. to manufacture sabirnetug, a monoclonal antibody for Alzheimer's therapy. 👥 The collaboration will cover the manufacturing of the drug substance at Lonza's facility in New Hampshire. 🧪 Sabirnetug is the first antibody to demonstrate target engagement of toxic soluble amyloid beta oligomers. 💡 The antibody addresses an underlying cause of Alzheimer's by preventing these toxic oligomers from binding to neurons. ⏩ This collaboration will help accelerate the development of potential treatments for Alzheimer's disease. #BioprocessUpdates #Lonza #AcumenPharmaceuticals #sabirnetug #monoclonalantibody #Alzheimerstherapy #collaboration #manufacturing #drugsubstance #amyloidbetaoligomers #neurons #underlyingcause #potentialtreatments #acceleratedevelopment #Alzheimersdisease ▷ Read the full article here: 📎 https://lnkd.in/dPvCJ4Fm

📅 Add this to your 2024 calendar! 📅   Returning to Boston in May, the 4𝒕𝒉 𝑳𝒊𝒈𝒂𝒔𝒆 𝑻𝒂𝒓𝒈𝒆𝒕𝒊𝒏𝒈 𝑫𝒓𝒖𝒈 𝑫𝒊𝒔𝒄𝒐𝒗𝒆𝒓𝒚 𝑺𝒖𝒎𝒎𝒊𝒕 will unite 80+ ligase experts dedicated to tackling ligase bottlenecks through data-driven presentations, technical discussions, and interactive sessions, unlocking the potential of E3 ligases for novel degrading or modulating drug targets.   So, if novel E3 ligases, streamlining ligase ligand screening, structural characterization, and assaying therapeutic efficacy is top of your list to master in 2024, don't miss out on hearing the latest developments and innovations from Nurix Therapeutics, NysnoBio, Arvinas, AbbVie, Vicinitas Therapeutics, Lyterian Therapeutics, Asha Therapeutics, The Structural Genomics Consortium (SGC), Novartis, GSK, The Francis Crick Institute and many more! To explore all expert-led talks, view the 2024 Agenda here: 👉 https://lnkd.in/eB68U7Q3 👈 #Ligase #E3Ligase #TPD #SmallMolecules #PROTAC #MolecularGlue #UPS #Undruggable

On #WorldAlzheimersDay, we reflected on the urgency of finding solutions for this devastating disease. At InVivo Biosystems, we are proud to play a part in the ongoing fight against Alzheimer’s through our innovative RapidGen™ preclinical platform. RapidGen™ revolutionizes drug discovery by starting with AI-powered target selection, followed by the use of validated, humanized Alzheimer's Disease models and high-throughput phenotypic screening. This streamlined process accelerates the delivery of IND-enabling data, empowering pharmaceutical companies to make faster, more informed decisions—advancing potential treatments to the clinic without added financial strain. Learn more about how the RapidGen™ platform is accelerating preclinical development here: https://lnkd.in/gUH88Jbp #AlzheimersDisease #PreclinicalResearch #InVivoBiosystems #DrugDiscovery #DrugDevelopment #Innovation #BiotechInnovation #NeurodegenerativeDisease